var data={"title":"Amphotericin B lipid complex: Pediatric drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Amphotericin B lipid complex: Pediatric drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/5635?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=amphotericin-b-lipid-complex-drug-information\" class=\"drug drug_general\">see &quot;Amphotericin B lipid complex: Drug information&quot;</a> and <a href=\"topic.htm?path=amphotericin-b-lipid-complex-patient-drug-information\" class=\"drug drug_patient\">see &quot;Amphotericin B lipid complex: Patient drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F134818\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Abelcet</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F134819\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Abelcet</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1045118\" class=\"list_set htclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Therapeutic Category</span>\n    <ul>\n      <li>\n        <span class=\"list-set-name\">Antifungal Agent, Systemic</span></li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F11432527\" class=\"block don drugH1Div\"><span class=\"drugH1\">Dosing: Neonatal</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Medication errors, including deaths, have resulted from confusion between lipid-based forms of amphotericin (Abelcet, Amphotec, AmBisome) and conventional amphotericin B for injection.</b> Lipid-based and conventional formulations are <b>not</b> interchangeable and have different dosing recommendations. Overdoses have occurred when conventional formulations were dispensed inadvertently for lipid-based products.</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">\n      <b>Note:</b> In neonates, lipid formulations of amphotericin have poorer penetration into the central nervous system, kidneys, urinary tract, and eyes than conventional amphotericin and are not preferred in most cases (IDSA [Pappas 2016]; <i>Red Book</i> [AAP 2015]; Turkova 2011).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">\n      <b>Candidiasis, invasive:</b> Limited data available: IV: 3 to 5 mg/kg/dose once daily; treatment should continue for at least 2 weeks after the first negative blood culture and signs and symptoms have resolved (IDSA [Pappas 2016]); a pharmacokinetic study reported use  in neonates with GA ranging from 24 to 41 weeks and weight ranging from 0.48 to 4.9 kg (W&uuml;rthwein 2005)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1045111\" class=\"block dos drugH1Div\"><span class=\"drugH1\">Dosing: Usual</span><p>(For additional information <a href=\"topic.htm?path=amphotericin-b-lipid-complex-drug-information\" class=\"drug drug_general\">see &quot;Amphotericin B lipid complex: Drug information&quot;</a>)</p>\n    <p style=\"text-indent:0em;\">\n      <b>Medication errors, including deaths, have resulted from confusion between lipid-based forms of amphotericin (Abelcet, Amphotec, AmBisome) and conventional amphotericin B for injection.</b> Lipid-based and conventional formulations are <b>not</b> interchangeable and have different dosing recommendations. Overdoses have occurred when conventional formulations were dispensed inadvertently for lipid-based products.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pediatric: <b>Note:</b> For patients who experience nonanaphylactic infusion-related immediate reactions, premedicate with the following drugs 30 to 60 minutes prior to drug administration: NSAID (with or without diphenhydramine) or acetaminophen with diphenhydramine or hydrocortisone. If the patient experiences rigors during the infusion, meperidine may be administered.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>General dosing, susceptible infections:</b> Infants, Children, and Adolescents: IV: 5 mg/kg/dose once daily</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>\n        <i>Aspergillosis</i></b>\n      <b>, treatment:</b></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Invasive: Infants, Children, and Adolescents: IV: 5 mg/kg/dose once daily; duration of treatment depends on site of infection, extent of disease, and level of immunosuppression (IDSA [Walsh 2008])</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Endocarditis: Children and Adolescents: IV: 3 to 5 mg/kg/dose once daily with or without flucytosine (AHA [Baltimore 2015])</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Blastomycosis</b>\n      <b>, invasive:</b> Infants, Children, and Adolescents: IV: 3 to 5 mg/kg/dose once daily for initial therapy usually for 1 to 2 weeks, if CNS infection 4 to 6 weeks may be needed; follow with oral itraconazole for a total of 12 months (IDSA [Chapman 2008])</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>\n        <i>Candidiasis</i></b>\n      <b>, treatment:</b></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Invasive (Independent of HIV status): Infants, Children, and Adolescents: IV: 3 to 5 mg/kg/dose once daily (IDSA [Pappas 2016]); <b>Note:</b> In HIV-exposed/-positive patients, doses at the higher end of the range may be considered (5 mg/kg/day) (HHS [OI pediatric 2013]).</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Endocarditis: Infants, Children, and Adolescents: IV: 3 to 5 mg/kg/dose once daily with or without flucytosine (AHA [Baltimore 2015]; IDSA [Pappas 2016])</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Esophageal: HIV-exposed/-positive: Adolescents: IV: 3 to 4 mg/kg/dose once daily for 14 to 21 days (HHS [OI adult 2016])</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>\n        <i>Coccidioidomycosis</i></b>\n      <b>, invasive:</b></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Non-HIV-exposed/-infected:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">\n      <i>Disseminated infection, nonpulmonary:</i> Infants, Children, and Adolescents: IV: 2 to 5 mg/kg/dose once daily with or without concomitant azole antifungal therapy (IDSA [Galgiani 2005])</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">\n      <i>Pulmonary infection, diffuse: </i>Infants, Children, and Adolescents: IV: 2 to 5 mg/kg/dose once daily for several weeks, followed by an oral azole antifungal for a total length of therapy &ge;12 months (IDSA [Galgiani 2005])</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">HIV-exposed/-infected: <i>Non-CNS infection, severe (ie, diffuse pulmonary or severely ill with extrathoracic, disseminated disease):</i></p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Infants and Children: IV: 5 mg/kg/dose once daily until clinical improvement; dose may be increased to as high as 10 mg/kg/dose once daily for life-threatening infection (HHS [OI pediatric 2013])</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Adolescents: IV: 3 to 5 mg/kg/dose once daily until clinical improvement, then switch to fluconazole or itraconazole (HHS [OI adult 2016])</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>\n        <i>Cryptococcosis:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Disseminated (non-CNS or severe pulmonary disease)</i></p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Infants and Children (independent of HIV status): IV: 5 mg/kg/dose once daily; for severe infection in HIV-exposed/-infected patients, may consider the addition of flucytosine (HHS [OI pediatric 2013]; IDSA [Perfect 2010])</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Adolescents:</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Non-HIV-exposed: IV: 5 mg/kg/dose once daily (with flucytosine) for &ge;4 weeks may be used for severe pulmonary cryptococcosis or for cryptococcemia with evidence of high fungal burden, followed by oral fluconazole. <b>Note:</b> If flucytosine is not given or treatment is interrupted, consider prolonging induction therapy for an additional 2 weeks (IDSA [Perfect 2010]).</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">HIV-exposed/-positive: IV: Induction therapy: 5 mg/kg/dose once daily with flucytosine for at least 2 weeks, followed by oral fluconazole or itraconazole (HHS [OI adult 2016]).</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Meningitis:</i></p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Infants and Children:</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Non-HIV-exposed/-positive: IV: 5 mg/kg/dose once daily with or without oral flucytosine for a minimum 2-week induction; combination with flucytosine is the preferred treatment (IDSA [Perfect 2010])</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">HIV-exposed/-positive: IV: 5 mg/kg/dose once daily plus flucytosine or fluconazole; <b>Note:</b> Minimum 2-week induction, followed by consolidation and chronic suppressive therapy; a longer duration of induction therapy may be necessary if CSF is not negative or lack of clinical improvement (HHS [OI pediatric 2013])</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Adolescents:</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Non-HIV-exposed/-positive; nontransplant patients: IV: Induction therapy: 5 mg/kg/dose once daily (with flucytosine) for &ge;4 weeks followed by oral fluconazole; should be used as an alternative to conventional amphotericin B in patients with renal concerns. <b>Note:</b> If flucytosine is not given or treatment is interrupted, consider prolonging induction therapy for an additional 2 weeks (IDSA [Perfect 2010]).</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">HIV-exposed/-positive: IV: Induction therapy: 5 mg/kg/dose once daily with flucytosine for at least 2 weeks, followed by fluconazole for consolidation therapy (HHS [OI adult 2016]; IDSA [Perfect 2010]). <b>Note:</b> If flucytosine is not given due to intolerance, duration of amphotericin B lipid complex therapy should be 4 to 6 weeks (IDSA [Perfect 2010]).</p>\n    <p style=\"text-indent:-2em;margin-left:10em;\">Transplant patients: Induction therapy: IV: 5 mg/kg/dose once daily (with flucytosine) for at least 2 weeks followed by oral fluconazole. <b>Note:</b> If flucytosine is not given, duration of therapy should be 4 to 6 weeks (IDSA [Perfect 2010]).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Histoplasmosis: </b></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Non-HIV-exposed/-positive: <i>Disseminated (non-CNS) or pulmonary disease:</i> Infants, Children, and Adolescents: IV: 5 mg/kg/dose once daily for 1 to 2 weeks followed by oral itraconazole for a total of 12 weeks; conventional amphotericin B typically preferred (IDSA [Wheat 2007])</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">HIV-exposed/-positive: <i>Disseminated disease (moderately severe to severe):</i> Adolescents: IV: 3 mg/kg/dose once daily for at least 2-week induction, followed by oral itraconazole (HHS [OI adult 2016])</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Leishmaniasis, visceral (HIV-exposed/-positive)</b> (HHS [OI adult 2016]):</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Treatment: Adolescents: IV: 2 to 4 mg/kg/dose once daily <b>or</b> an interrupted schedule of 4 mg/kg/dose on days 1 to 5, and on days 10, 17, 24, 31, and 38  to achieve a total dose of 20 to 60 mg/kg</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Chronic maintenance: Adolescents: IV: 3 mg/kg/dose every 21 days; <b>Note:</b> Use reserved for patients with visceral infection and CD4 count &lt;200 cells/mm<sup>3</sup></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Sporotrichosis </b>\n      <b>infection </b>(IDSA [Kauffman 2007])<b>:</b> Adolescents:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Meningeal: IV: 5 mg/kg/dose once daily for 4 to 6 weeks, followed by oral itraconazole</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Pulmonary, osteoarticular, and disseminated: IV: 3 to 5 mg/kg/dose once daily, followed by oral itraconazole after a favorable response is seen with amphotericin initial therapy</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Adult: <b>Note:</b> For patients who experience infusion-related immediate reactions, premedicate with the following drugs 30 to 60 minutes prior to drug administration: NSAID (with or without diphenhydramine) or acetaminophen with diphenhydramine or hydrocortisone 50 to 100 mg. If the patient experiences rigors during the infusion, meperidine may be administered. <b>General dosing, susceptible infection:</b> IV: 5 mg/kg/dose once daily</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Dosing adjustment in renal impairment: </b>Infants, Children, Adolescents, and Adults:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Manufacturer&rsquo;s recommendations: There are no dosage adjustments provided in manufacturer's labeling (has not been studied).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Alternate recommendations: The following adjustments have been recommended (Aronoff 2007):</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Hemodialysis: No supplemental dosage necessary</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Peritoneal dialysis: No supplemental dosage necessary</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Continuous renal replacement therapy (CRRT): No supplemental dosage necessary</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Dosing adjustment in hepatic impairment:</b> There are no dosage adjustments provided in manufacturer's labeling (has not been studied).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F134799\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Suspension, Intravenous: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Abelcet: 5 mg/mL (20 mL)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F134785\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Availability (US)</span>\n    <p style=\"text-indent:0em;display:inline\">No</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1045121\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:0em;display:inline\">Parenteral: IV: Prior to administration, amphotericin B lipid complex 5 mg/mL concentrated suspension must be diluted. Flush line with D<sub>5</sub>W prior to infusion. Gently shake the IV container of diluted drug to insure that contents are thoroughly mixed then administer at a rate of 2.5 mg/kg/hour (over 2 hours). The manufacturer recommends that an in-line filter should <b>not</b> be used during administration of amphotericin B lipid complex. If infusion time exceeds 2 hours, mix the contents by gently rotating the infusion bag every 2 hours.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F134812\" class=\"block sts drugH1Div\"><span class=\"drugH1\">Storage/Stability</span>\n    <p style=\"text-indent:0em;display:inline\">Intact vials should be stored at 2&deg;C to 8&deg;C (35&deg;F to 46&deg;F); do not freeze. Protect intact vials from exposure to light. Solutions in D5W for infusion are stable for 48 hours under refrigeration and for an additional 6 hours at room temperature.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1045120\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:0em;display:inline\">Treatment of invasive fungal infections in patients who are refractory to or intolerant of conventional amphotericin B therapy (FDA approved in children and adults)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F134847\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">High alert medication:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">The Institute for Safe Medication Practices (ISMP) includes this medication among its list of drugs which have a heightened risk of causing significant patient harm when used in error.</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Other safety concerns:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Lipid-based amphotericin formulations (Abelcet) may be confused with conventional formulations (Fungizone) or with other lipid-based amphotericin formulations (amphotericin B liposomal [AmBisome]; amphotericin B cholesteryl sulfate complex [Amphotec]) </p>\n        <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Large overdoses have occurred when conventional formulations were dispensed inadvertently for lipid-based products. Single daily doses of conventional amphotericin formulation never exceed 1.5 mg/kg.</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F134845\" class=\"block arm drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:0em;display:inline\">Nephrotoxicity and infusion-related hyperpyrexia, rigor, and chilling are reduced relative to amphotericin deoxycholate.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cardiovascular: Cardiac arrest, chest pain, hypertension, hypotension</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Central nervous system: Chills, headache, pain</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dermatologic: Skin rash</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Endocrine &amp; metabolic: Hypokalemia</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Gastrointestinal: Abdominal pain, diarrhea, gastrointestinal hemorrhage, nausea, vomiting</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hematologic &amp; oncologic: Anemia, leukopenia, thrombocytopenia</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hepatic: Hyperbilirubinemia</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Infection: Infection, sepsis</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Renal: Increased serum creatinine, renal failure</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Respiratory: Dyspnea, respiratory failure, respiratory tract disease</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Miscellaneous: Fever, multi-organ failure</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Rare but important or life-threatening: Acute hepatic failure, anaphylactoid reaction, anuria, asthma, blood coagulation disorder, brain disease, bronchospasm, cardiac arrhythmia, cardiomyopathy, cerebrovascular accident, cholangitis, cholecystitis, deafness, dysuria, eosinophilia, erythema multiforme, exfoliative dermatitis, extrapyramidal reaction, hearing loss, hematologic disease, hemoptysis, hepatic sinusoidal obstruction syndrome (formerly known as hepatic veno-occlusive disease), hepatitis, hepatomegaly, hepatotoxicity, hypercalcemia, hyperkalemia, hypersensitivity reaction, hypocalcemia, hypomagnesemia, increased blood urea nitrogen, increased serum transaminases, injection site reaction, jaundice, leukocytosis, myasthenia, myocardial infarction, oliguria, peripheral neuropathy, pleural effusion, pulmonary edema, pulmonary embolism, renal insufficiency, renal tubular acidosis, seizure, shock, tachycardia, thrombophlebitis, ventricular fibrillation, vertigo (transient), visual impairment</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F134805\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:0em;display:inline\">Hypersensitivity to amphotericin or any component of the formulation</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F134789\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Anaphylaxis: Has been reported with amphotericin B-containing drugs; facilities for cardiopulmonary resuscitation should be available during administration due to the possibility of anaphylactic reaction. If severe respiratory distress occurs, the infusion should be immediately discontinued; during the initial dosing, the drug should be administered under close clinical observation.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Infusion reactions: Acute reactions (including fever and chills) may occur 1-2 hours after starting an intravenous infusion. These reactions are usually more common with the first few doses and generally diminish with subsequent doses. Infusion has been rarely associated with hypotension, bronchospasm, arrhythmias, and shock.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>\n          <b>Disease-related concerns</b>:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Heart failure: In a scientific statement from the American Heart Association, amphotericin has been determined to be an agent that may cause direct myocardial toxicity (magnitude: moderate/major) (AHA [Page 2016]).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concurrent drug therapy issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Antineoplastics: Concurrent use with antineoplastic agents may enhance the potential for renal toxicity, bronchospasm or hypotension; use with caution.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Nephrotoxic drugs: Concurrent use of amphotericin B with other nephrotoxic drugs may enhance the potential for drug-induced renal toxicity.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Other warnings/precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Leukocyte transfusions: Acute pulmonary toxicity has been reported in patients receiving leukocyte transfusions and amphotericin B; amphotericin B lipid complex and concurrent leukocyte transfusions are not recommended.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13298745\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">None known.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F134793\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=12660&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Alfuzosin: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Amifostine: Blood Pressure Lowering Agents may enhance the hypotensive effect of Amifostine.  Management: When amifostine is used at chemotherapy doses, blood pressure lowering medications should be withheld for 24 hours prior to amifostine administration. If blood pressure lowering therapy cannot be withheld, amifostine should not be administered.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Aminoglycosides: Amphotericin B may enhance the nephrotoxic effect of Aminoglycosides. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Antifungal Agents (Azole Derivatives, Systemic): May diminish the therapeutic effect of Amphotericin B.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Antipsychotic Agents (Second Generation [Atypical]): Blood Pressure Lowering Agents may enhance the hypotensive effect of Antipsychotic Agents (Second Generation [Atypical]). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Barbiturates: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Benperidol: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Blood Pressure Lowering Agents: May enhance the hypotensive effect of Hypotension-Associated Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Brimonidine (Topical): May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bromperidol: Blood Pressure Lowering Agents may enhance the hypotensive effect of Bromperidol. Bromperidol may diminish the hypotensive effect of Blood Pressure Lowering Agents. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cardiac Glycosides: Amphotericin B may enhance the adverse/toxic effect of Cardiac Glycosides. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Colistimethate: Amphotericin B may enhance the nephrotoxic effect of Colistimethate. <i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Corticosteroids (Orally Inhaled): May enhance the hypokalemic effect of Amphotericin B.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Corticosteroids (Systemic): May enhance the hypokalemic effect of Amphotericin B.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CycloSPORINE (Systemic): Amphotericin B may enhance the nephrotoxic effect of CycloSPORINE (Systemic). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Diazoxide: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dronabinol: May increase the serum concentration of Amphotericin B. Specifically, dronabinol may displace amphotericin B from its protein-binding sites, leading to an increased concentration of active, unbound drug.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">DULoxetine: Blood Pressure Lowering Agents may enhance the hypotensive effect of DULoxetine. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Flucytosine: Amphotericin B may enhance the adverse/toxic effect of Flucytosine. This may be related to the adverse effects of amphotericin B on renal function. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Foscarnet: May enhance the nephrotoxic effect of Amphotericin B.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ganciclovir-Valganciclovir: May enhance the nephrotoxic effect of Amphotericin B.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Herbs (Hypotensive Properties): May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hypotension-Associated Agents: Blood Pressure Lowering Agents may enhance the hypotensive effect of Hypotension-Associated Agents. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Levodopa: Blood Pressure Lowering Agents may enhance the hypotensive effect of Levodopa. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Lormetazepam: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Methoxyflurane: May enhance the nephrotoxic effect of Amphotericin B.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Molsidomine: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Naftopidil: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nicergoline: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nicorandil: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nitroprusside: Blood Pressure Lowering Agents may enhance the hypotensive effect of Nitroprusside. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Obinutuzumab: May enhance the hypotensive effect of Blood Pressure Lowering Agents. Management: Consider temporarily withholding blood pressure lowering medications beginning 12 hours prior to obinutuzumab infusion and continuing until 1 hour after the end of the infusion.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pentoxifylline: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pholcodine: Blood Pressure Lowering Agents may enhance the hypotensive effect of Pholcodine. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Phosphodiesterase 5 Inhibitors: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Prostacyclin Analogues: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Quinagolide: May enhance the hypotensive effect of Blood Pressure Lowering Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Saccharomyces boulardii: Antifungal Agents (Systemic, Oral) may diminish the therapeutic effect of Saccharomyces boulardii. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sodium Stibogluconate: Amphotericin B may enhance the cardiotoxic effect of Sodium Stibogluconate. <i> Risk D: Consider therapy modification</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F134795\" class=\"block prf drugH1Div\"><span class=\"drugH1\">Pregnancy Risk Factor</span>\n    <p style=\"text-indent:0em;display:inline\">B (<a href=\"image.htm?imageKey=DRUG%2F50021\" class=\"graphic graphic_table\">show table</a>)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13314059\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Adverse events were not observed in animal reproduction studies. Amphotericin crosses the placenta and enters the fetal circulation. Amphotericin B is recommended for the treatment of serious, systemic fungal diseases in pregnant women, refer to current guidelines (IDSA [Pappas 2016]; King 1998; Pilmus 2015).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1045117\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">BUN, serum creatinine, liver function tests, serum electrolytes (especially potassium and magnesium), CBC; vital signs, I &amp; O</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F134788\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Binds to ergosterol altering cell membrane permeability in susceptible fungi and causing leakage of cell components with subsequent cell death. Proposed mechanism suggests that amphotericin causes an oxidation-dependent stimulation of macrophages.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F134804\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics (Adult data unless noted)</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Note:</b> Exhibits nonlinear kinetics; volume of distribution and clearance from blood increases with increasing dose.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Distribution: High tissue concentration found in the liver, spleen, and lung ; V<sub>d</sub>: Increases with higher doses (likely reflects increased uptake by tissues); 131 L/kg with 5 mg/kg/day</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Half-life elimination: 173 hours following multiple doses</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Excretion: 0.9% of dose excreted in urine over 24 hours; effects of hepatic and renal impairment on drug disposition are unknown</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1045125\" class=\"block adi drugH1Div\"><span class=\"drugH1\">Additional Information</span>\n    <p style=\"text-indent:0em;display:inline\">The lipid portion of amphotericin B lipid complex formulation contains 0.045 kcal per 5 mg; for patients receiving parenteral nutrition, adjustment to the amount of lipids may be necessary (Sacks 1997).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F16322988\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Suspension</b> (Abelcet Intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">5 mg/mL (20 mL): $235.80</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F6038525\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Abelcet (AE, AR, AT, AU, BB, BE, BR, CR, CY, CZ, DK, DO, ES, FI, FR, GB, GR, GT, HN, HR, HU, IE, IT, LB, LU, NI, NL, NZ, PA, PL, PT, SE, SG, SK, SV, TR);</li>\n      <li>Ampholip (IN, LK, VN)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    Abelcet (amphotericin lipid complex) [prescribing information]. Gaithersburg, MD: Sigma-Tau Pharmaceuticals, Inc; March 2013.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Adler-Shohet F, Waskin H, and Lieberman JM, &quot;Amphotericin B Lipid Complex for Neonatal Invasive Candidiasis,&quot; <i>Arch Dis Child Fetal Neonatal Ed</i>, 2001, 84(2):F131-3.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/amphotericin-b-lipid-complex-pediatric-drug-information/abstract-text/11207232/pubmed\" target=\"_blank\" id=\"11207232\">11207232</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    American Academy of Pediatrics (AAP). In: Kimberlin DW, Brady MT, Jackson MA, Long SA, eds. <i>Red Book: 2015 Report of the Committee on Infectious Diseases</i>. 30th ed. Elk Grove Village, IL: American Academy of Pediatrics; 2015.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Aronoff GR, Bennett WM, Berns JS, et al, <i>Drug Prescribing in Renal Failure: Dosing Guidelines for Adults and Children</i>, 5th ed, Philadelphia, PA: American College of Physicians, 2007, 97, 169.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Baltimore RS, Gewitz M, Baddour LM, et al. Infective endocarditis in childhood: 2015 update: A scientific statement from the American Heart Association. <i>Circulation</i>. 2015;132(15):1487-1515.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/amphotericin-b-lipid-complex-pediatric-drug-information/abstract-text/26373317/pubmed\" target=\"_blank\" id=\"26373317\">26373317</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Cetin H, Yalaz M, Akisu M, et al, &quot;The Efficacy of Two Different Lipid-Based Amphotericin B in Neonatal Candida Septicemia,&quot; <i>Pediatr Int</i>, 2005, 47(6):676-80.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/amphotericin-b-lipid-complex-pediatric-drug-information/abstract-text/16354223/pubmed\" target=\"_blank\" id=\"16354223\">16354223</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Chapman SW, Dismukes WE, Proia LA, et al, &quot;Clinical Practice Guidelines for the Management of Blastomycosis: 2008 Update by the Infectious Diseases Society of America,&quot; <i>Clin Infect Dis</i>, 2008, 46(12):1801-12.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/amphotericin-b-lipid-complex-pediatric-drug-information/abstract-text/18462107/pubmed\" target=\"_blank\" id=\"18462107\">18462107</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Galgiani JN, Ampel NM, Blair JE, et al, &quot;Coccidioidomycosis,&quot; <i>Clin Infect Dis</i>, 2005, 41(9):1217-23.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/amphotericin-b-lipid-complex-pediatric-drug-information/abstract-text/16206093/pubmed\" target=\"_blank\" id=\"16206093\">16206093</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    HHS. Guidelines for the prevention and treatment of opportunistic infections among HIV-exposed and HIV-infected children: recommendations from  the National Institutes of Health, Centers for Disease Control and Prevention, the HIV Medicine Association of the Infectious Diseases Society of America, the Pediatric Infectious Diseases Society, and the American Academy of Pediatrics. November 6, 2013. Available at <a href=\"http://aidsinfo.nih.gov/\" target=\"_blank\">http://aidsinfo.nih.gov</a></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    HHS Panel on Opportunistic Infections in HIV-Infected Adults and Adolescents. Guidelines for the prevention and treatment of opportunistic infections in HIV-infected adults and adolescents: recommendations from the Centers for Disease Control and Prevention, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America. November 2016. Available at <a href=\"http://aidsinfo.nih.gov/contentfiles/lvguidelines/adult_oi.pdf\" target=\"_blank\">http://aidsinfo.nih.gov/contentfiles/lvguidelines/adult_oi.pdf</a>. Accessed December 5, 2016<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/amphotericin-b-lipid-complex-pediatric-drug-information/abstract-text/11705428/pubmed\" target=\"_blank\" id=\"11705428\">11705428</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    King CT, Rogers PD, Cleary JD, et al, &quot;Antifungal Therapy During Pregnancy,&quot; <i>Clin Infect Dis</i>, 1998, 27(5):1151-60.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/amphotericin-b-lipid-complex-pediatric-drug-information/abstract-text/9827262/pubmed\" target=\"_blank\" id=\"9827262\">9827262</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Mactal-Haaf C, Hoffman M, and Kuchta A, &quot;Use of Anti-infective Agents During Lactation, Part 3: Antivirals, Antifungals, and Urinary Antiseptics,&quot; <i>J Hum Lact</i>, 2001, 17(2):160-6.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/amphotericin-b-lipid-complex-pediatric-drug-information/abstract-text/11847833/pubmed\" target=\"_blank\" id=\"11847833\">11847833</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Pappas PG, Kauffman CA, Andes DR, et al. Clinical practice guideline for the management of candidiasis: 2016 update by the Infectious Diseases Society of America. <i>Clin Infect Dis</i>. 2016;62(4):e1-50.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/amphotericin-b-lipid-complex-pediatric-drug-information/abstract-text/26679628/pubmed\" target=\"_blank\" id=\"26679628\">26679628</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Perfect JR, Dismukes WE, Dromer F, et al, &quot;Clinical Practice Guidelines for the Management of Cryptococcal Disease: 2010 Update by the Infectious Diseases Society of America,&quot; <i>Clin Infect Dis</i>, 2010, 50(3):291-322.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/amphotericin-b-lipid-complex-pediatric-drug-information/abstract-text/20047480/pubmed\" target=\"_blank\" id=\"20047480\">20047480</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Sacks GS and Cleary JD, &ldquo;Nutritional Impact of Lipid-Associated Amphotericin B Formulations,&rdquo; <i>Ann Pharmacother</i>, 1997, 31(1):121-2.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/amphotericin-b-lipid-complex-pediatric-drug-information/abstract-text/8997484/pubmed\" target=\"_blank\" id=\"8997484\">8997484</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Tunkel AR, Glaser CA, Bloch KC, et al, &ldquo;The Management of Encephalitis: Clinical Practice Guidelines from the Infectious Diseases Society of America,&rdquo; <i>Clin Infect Dis</i>, 2008, 47(3):303-27.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/amphotericin-b-lipid-complex-pediatric-drug-information/abstract-text/18582201/pubmed\" target=\"_blank\" id=\"18582201\">18582201</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Turkova A, Roilides E, Sharland M. Amphotericin B in neonates: deoxycholate or lipid formulation as first-line therapy - is there a 'right' choice? <i>Curr Opin Infect Dis</i>. 2011;24(2):163-171.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/amphotericin-b-lipid-complex-pediatric-drug-information/abstract-text/21301335 /pubmed\" target=\"_blank\" id=\"21301335 \">21301335 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Walsh TJ, Anaissie EJ, Denning DW, et al, &ldquo;Treatment of Aspergillosis: Clinical Practice Guidelines of the Infectious Diseases Society of America,&rdquo; <i>Clin Infect Dis</i>, 2008, 46(3):327-60.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/amphotericin-b-lipid-complex-pediatric-drug-information/abstract-text/18177225/pubmed\" target=\"_blank\" id=\"18177225\">18177225</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Wheat LJ, Freifeld AG, Kleiman MB, et al, &quot;Clinical Practice Guidelines for the Management of Patients With Histoplasmosis: 2007 Update by the Infectious Diseases Society of America,&quot; <i>Clin Infect Dis</i>, 2007, 45(7):807-25.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/amphotericin-b-lipid-complex-pediatric-drug-information/abstract-text/17806045/pubmed\" target=\"_blank\" id=\"17806045\">17806045</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    W&uuml;rthwein G, Groll AH, Hempel G, et al, &quot;Population Pharmacokinetics of Amphotericin B Lipid Complex in Neonates,&quot; <i>Antimicrob Agents Chemother</i>, 2005, 49(12):5092-8.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/amphotericin-b-lipid-complex-pediatric-drug-information/abstract-text/16304177/pubmed\" target=\"_blank\" id=\"16304177\">16304177</a>]</span></div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 12660 Version 111.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F134818\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F134819\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Therapeutic Category\" href=\"#F1045118\" class=\"outlineLink\">Therapeutic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Neonatal\" href=\"#F11432527\" class=\"outlineLink\">Dosing: Neonatal</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Usual\" href=\"#F1045111\" class=\"outlineLink\">Dosing: Usual</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F134799\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Availability (US)\" href=\"#F134785\" class=\"outlineLink\">Generic Availability (US)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F1045121\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Storage/Stability\" href=\"#F134812\" class=\"outlineLink\">Storage/Stability</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F1045120\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F134847\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F134845\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F134805\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F134789\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F13298745\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F134793\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Risk Factor\" href=\"#F134795\" class=\"outlineLink\">Pregnancy Risk Factor</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F13314059\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F1045117\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F134788\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics (Adult data unless noted)\" href=\"#F134804\" class=\"outlineLink\">Pharmacodynamics/Kinetics (Adult data unless noted)</a></li><li class=\"plainItem\"><a sectionName=\"Additional Information\" href=\"#F1045125\" class=\"outlineLink\">Additional Information</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F16322988\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F6038525\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_PED/12660|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=amphotericin-b-lipid-complex-drug-information\" class=\"drug drug_general\">Amphotericin B lipid complex: Drug information</a></li><li><a href=\"topic.htm?path=amphotericin-b-lipid-complex-patient-drug-information\" class=\"drug drug_patient\">Amphotericin B lipid complex: Patient drug information</a></li></ul></div></div>","javascript":null}